Circulating tumor cells: application as a biomarker for molecular characterization and predictor of survival in an all-comer solid tumor phase I clinical study

• Published in: PloS one 2013-08, Vol.8 (8), p.e58557-e58557
• Main Authors: Bao, Haifeng, Burke, Patricia A, Huang, Jiaqi, Chen, Xiaoru, Brohawn, Philip Z, Yao, Yihong, Lechleider, Robert J, Sikorski, Robert S, Buzoianu, Manuela, Zhang, Jianliang, Shi, Xiaoqing, Richman, Laura K, Lavallee, Theresa M
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antibodies; Biomarkers; Biomarkers, Tumor - metabolism; Blood; Breast cancer; Cancer; Cancer metastasis; Cancer research; Care and treatment; Clinical trials; Disease-Free Survival; Drug development; Drugs; Enumeration; Experimental design; Feasibility studies; Female; Gene expression; Gene Expression Profiling - methods; Gene Expression Regulation, Neoplastic; Growth factors; Humans; Immunoglobulins; Kinases; Male; Metastasis; Middle Aged; Neoplasms - blood; Neoplasms - metabolism; Neoplastic Cells, Circulating; Patients; Polymerase chain reaction; Probability; Prognosis; Prostate; Real-Time Polymerase Chain Reaction - methods; Solid tumors; Survival; Survival analysis; Time Factors; Tumor cells; Tumors
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0058557

Clinical development of cancer drugs has a low success rate. Prognostic and predictive biomarkers using minimally invasive approaches hold promise for increasing the probability of success by enabling disease characterization, patient selection and early detection of drug treatment effect. Enumeration and molecular characterization of circulating tumor cells (CTC) may address some of these needs, and thus were evaluated for utility in a Phase I solid tumor clinical study. Blood samples for CTC analysis were obtained from 24 cancer patients in a multi-center all-comer Phase I study of MEDI-575, a novel anti-PDGFRα antibody. Samples were taken at screening and analyzed for enumeration of CTC using the CellSearch(®) platform and for molecular characterization using a novel quantitative RT-PCR assay. Fifty-nine percent of the patients showed at least 1 CTC per 7.5 ml of blood at baseline. Progression-free survival (PFS) and overall survival (OS) of patients with 0 CTCs at baseline were longer than PFS and Os for patients with 1-3 and >3 CTCs (8.8 versus 1.4 and 1.3 months PFS, P = 0.02; 9.0 vs 7.4 and 3.5 months OS, P = 0.20, respectively). Patients with 0 CTC showed a greater percentage of stable disease than the other 2 groups with 1-3 and >3 CTCs (57% vs 29% and 0%). The multimarker qRT-PCR method detected CTC in 40% of the patients, and 80% of these patients were positive for pre-selected drug target genes. CTC enumeration of patients in an all-comer study is feasible and may allow for patient stratification for PFS and Os to evaluate the clinical response of investigational agents. Gene expression profiling of isolated CTC may provide a means for molecular characterization of selected tumor targets.